Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines

Molecular insights on basal-like breast cancer

(2012) Mev Dominguez Valentin et al.   BREAST CANCER RESEARCH AND TREATMENT

Bisphosphonates in oncology

(2011) Robert E. Coleman et al.   BONE

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors

(2011) Shikha Gaur et al.   CANCER LETTERS

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells

(2011) Linda S. Steelman et al.   CELL CYCLE

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance

(2010) Xinmin Zhao et al.   BREAST CANCER RESEARCH AND TREATMENT

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

(2010) R E Coleman et al.   BRITISH JOURNAL OF CANCER

Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process

(2010) G. Moriceau et al.   CANCER RESEARCH

Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells

(2010) Antje Hahnel et al.   Radiation Oncology

Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells

(2009) Tilman D. Rachner et al.   CANCER LETTERS

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

Risks and benefits of bisphosphonates

(2008) R E Coleman   BRITISH JOURNAL OF CANCER

Antitumor effects of bisphosphonates: Promising preclinical evidence

(2008) Theresa A. Guise   CANCER TREATMENT REVIEWS

Differential Effect of Doxorubicin and Zoledronic Acid on Intraosseous versus Extraosseous Breast Tumor Growth In vivo

(2008) P. D. Ottewell et al.   CLINICAL CANCER RESEARCH

Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer

(2008) Fred Saad et al.   JOURNAL OF CLINICAL ONCOLOGY

Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line

(2008) Francesco Fabbri et al.   Journal of Translational Medicine